Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer

Shenyu Zhu,Rongqian Wu,Xiangjin Liu,Bin Xie,Chunfa Xie,Shulin Li,Zhicheng Wu,Zuxiong Zhang,Zhixian Tang,Liang Gu
DOI: https://doi.org/10.1080/14796694.2024.2376513
2024-07-29
Abstract:Lung cancer is one of the most common malignancies worldwide, with non-small cell lung cancer (NSCLC) being the most common type. As understanding of precise treatment options for NSCLC deepens, circulating tumor DNA (ctDNA) has emerged as a potential biomarker that has become a research hotspot and may represent a new approach for the individualized diagnosis and treatment of NSCLC. This article reviews the applications of ctDNA for the early screening of patients with NSCLC, guiding targeted therapy and immunotherapy, evaluating chemotherapy and postoperative efficacy, assessing prognosis and monitoring recurrence. With the in-depth study of the pathogenesis of NSCLC, plasma ctDNA may become an indispensable part of the precise treatment of NSCLC, which has great clinical application prospects.
What problem does this paper attempt to address?